Xencor to Participate at Upcoming Investor Conferences

XNCR 11.26.2024

Full Press ReleaseSEC FilingsOur XNCR Tweets

About Gravity Analytica

Recent News

  • 12.04.2024 - 7th Annual Evercore HealthCONx Conference
  • 12.03.2024 - Piper Sandler 36th Annual Healthcare Conference
  • 11.26.2024 - Xencor to Participate at Upcoming Investor Conferences

Recent Filings

  • 01.13.2025 - 8-K Current report
  • 01.13.2025 - EX-99.1 EX-99.1
  • 12.04.2024 - 4 Statement of changes in beneficial ownership of securities

PASADENA, Calif.--(BUSINESS WIRE)--Nov. 26, 2024--Xencor, Inc.(NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company management will participate at multiple upcoming investor conferences:

  • Piper Sandler 36th Annual Healthcare ConferenceDate:Tuesday, December 3, 2024Presentation Time:2:00 p.m. ET/11:00 a.m. PTLocation:New York City
  • 7th AnnualEvercore HealthCONx ConferenceDate:Wednesday, December 4, 2024Presentation Time:3:50 p.m. ET/12:50 p.m. PTLocation:Coral Gables, Florida

Live webcasts of the presentations will be available under “Events & Presentations” in the Investors section of the Company’s website located atwww.xencor.com. Replays of the events will be available on theXencorwebsite for at least 30 days following the presentations.

AboutXencor

Xencoris a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and other serious diseases. More than 20 candidates engineered withXencor'sXmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners.Xencor'sXmAb engineering technology enables small changes to a protein’s structure that result in new mechanisms of therapeutic action. For more information, please visitwww.xencor.com.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241126889211/en/

Charles Lilescliles@xencor.com(626) 737-8118

Source:Xencor, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com